How starting a GLP-1 medicine changes food reactions and choices.
Official title: Exploring the Influence of GLP-1 Medication on Food Attitudes and Selection in a Virtual Reality Buffet
Run by Penn State University · NCT06843512 · Data updated 2026-11-12
We will see if starting a GLP-1 medication changes how adults with overweight or obesity react to food and the foods they choose.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Penn State University Academic / other |
| Locations | 1 site (State College, Pennsylvania) |
| Status | Recruiting |
| Started | July 15, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | September 10, 2025 |
| Trial ID | NCT06843512 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a BMI over 25 who were prescribed a GLP-1 medication within the past two weeks, fluent in English, and without prior cognitive or physical disability are ideal candidates.
✕Probably not a fit
People under 18, those without overweight or obesity, those already on GLP-1 for more than two weeks or using compound GLP-1s, non-English speakers, or those with prior cognitive or physical disabilities are unlikely to be eligible or benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with overweight or obesity who are newly prescribed a GLP-1 medication are enrolled and tested either before or within two weeks of starting the drug and again after three months. Researchers collect measures of food reactivity and selection using behavioral tasks and the Health, Ingestive Behavior, and Technology Laboratory facilities, possibly including virtual-reality food-choice simulations. The study excludes people with prior cognitive or physical disabilities, dyslexia, epilepsy, or limited English fluency, and does not include those already on GLP-1 for more than two weeks or taking compound GLP-1 medications. Data are intended to describe changes in attitudes toward food and patterns of nutrient selection during the early course of GLP-1 treatment.
Why it matters
Potential benefit: If successful, the findings could help clinicians and patients maintain appropriate nutrient balance and make better food choices while using GLP-1 medications.
How similar studies have gone: Previous research shows GLP-1 drugs commonly reduce appetite and shift food preferences, but few studies have measured detailed real-time food choice or virtual-reality–based behavior during the first months of treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (18+) with overweight or obesity (BMI \>25 kg/m2) * Not currently taking an incretin-based medication at baseline * Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia) * Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Fluent in English Exclusion Criteria: * Adults (18+) without overweight or obesity * \<18 years of age at time of testing * Adults not taking a GLP-1 Medication * Adults taking a compound GLP-1 * Adults on GLP-1 medication for longer than 2 weeks at baseline * Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Not fluent in English
Where it's running
-
Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University
State College, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Travis Masterson — The Pennsylvania State University
- Study coordinator: Christina M Blackmon
- Email: cmb8633@psu.edu
- Phone: 425-499-8049
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
15-year outcomes after sleeve gastrectomy in France
This study looks at how people who had sleeve gastrectomy have fared over 15 years to see long-term weight changes and health effects.
-
Do GLP-1 medicines affect breastmilk production and milk quality after pregnancy
This study will test whether weight loss from injected GLP-1 receptor agonists changes how much milk moms produce or the nutritional makeup of their breast milk.
-
Nudges to steer college students toward healthier beverage choices
Four groups of Chinese college students will try different nudges to see if it changes their choice between sugary and sugar-free drinks.
-
Personalized 26-week program to help keep weight off
This 26-week program tests whether tailored messages, weekly check-ins and weighing, and optional health coaching help adults who recently lost at least 7% of their weight keep it off.
-
HRS9531 PK in adults with different liver function
This Phase 1 study tests how HRS9531 behaves in the body and whether it is safe in people with mild, moderate liver impairment and those with normal liver function.
-
Fasted versus fed aerobic exercise for weight loss and heart health
This 16-week program will see if doing aerobic exercise before breakfast (fasted) versus after eating helps adults with overweight or obesity lose more weight and improve heart-related measures.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.